A novel drug reduces the monthly frequency of seizure in adults with focal epilepsy

The effect of a novel Kv7.2/Kv7.3 potassium channel opener XEN1101 in reducing monthly seizure frequency in adults.

Continuing surveillance of emerging disease threats is vital for public health, national security

The advance of H5N1 bird flu reminds us that novel pathogens remain a stubborn threat. Although a full-blown pandemic doesn’t appear imminent, the virus’s ability

January 10, 2025

Socioeconomic status may not clearly predict the heart health of racial and ethnic groups

Improvements in socioeconomic status (education, income, employment status and health insurance) on ideal cardiovascular health may not benefit people from all racial or ethnic groups

September 13, 2023

Berotralstat: A promising oral treatment for hereditary angioedema with normal C1-inhibitor

BioCryst Pharmaceuticals, Inc. today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction

June 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.